DrugCite
Search

HUMATROPE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Humatrope Adverse Events Reported to the FDA Over Time

How are Humatrope adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Humatrope, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Humatrope is flagged as the suspect drug causing the adverse event.

Most Common Humatrope Adverse Events Reported to the FDA

What are the most common Humatrope adverse events reported to the FDA?

Hospitalisation
84 (1.47%)
Headache
72 (1.26%)
Fatigue
63 (1.11%)
Malaise
63 (1.11%)
Fall
60 (1.05%)
Asthenia
58 (1.02%)
Vomiting
57 (1%)
Convulsion
55 (.97%)
Incorrect Dose Administered
54 (.95%)
Nausea
53 (.93%)
Cerebrovascular Accident
52 (.91%)
Show More Show More
Epiphysiolysis
47 (.82%)
Drug Dose Omission
44 (.77%)
Weight Increased
43 (.75%)
Diarrhoea
38 (.67%)
Pain
38 (.67%)
Dehydration
37 (.65%)
Pneumonia
37 (.65%)
Pyrexia
37 (.65%)
Pituitary Tumour Recurrent
36 (.63%)
Weight Decreased
35 (.61%)
Memory Impairment
34 (.6%)
Brain Neoplasm
33 (.58%)
Arthralgia
32 (.56%)
Visual Acuity Reduced
32 (.56%)
Oedema Peripheral
31 (.54%)
Syncope
31 (.54%)
Death
29 (.51%)
Dizziness
28 (.49%)
Neoplasm Recurrence
28 (.49%)
Chest Pain
27 (.47%)
Loss Of Consciousness
26 (.46%)
Confusional State
25 (.44%)
Feeling Abnormal
25 (.44%)
Condition Aggravated
24 (.42%)
Hypoaesthesia
24 (.42%)
Medical Device Complication
24 (.42%)
Anaemia
23 (.4%)
Depression
23 (.4%)
Myocardial Infarction
23 (.4%)
Neoplasm Progression
23 (.4%)
Surgery
23 (.4%)
Craniopharyngioma
22 (.39%)
Dyspnoea
22 (.39%)
Pituitary Tumour Benign
22 (.39%)
Nervousness
21 (.37%)
Hypertension
20 (.35%)
Medication Error
20 (.35%)
Meningioma
20 (.35%)
Back Pain
19 (.33%)
Drug Ineffective
19 (.33%)
Off Label Use
19 (.33%)
Urinary Tract Infection
19 (.33%)
Cardiac Disorder
18 (.32%)
Knee Arthroplasty
18 (.32%)
Muscular Weakness
18 (.32%)
Hypotension
17 (.3%)
Pain In Extremity
17 (.3%)
Pituitary Tumour
17 (.3%)
Sepsis
17 (.3%)
Blindness
16 (.28%)
Brain Oedema
16 (.28%)
Head Injury
16 (.28%)
Infection
16 (.28%)
Mobility Decreased
16 (.28%)
Renal Failure
16 (.28%)
Sleep Apnoea Syndrome
16 (.28%)
Viral Infection
16 (.28%)
Breast Cancer
15 (.26%)
Cough
15 (.26%)
Diabetes Mellitus
15 (.26%)
Obstructive Airways Disorder
15 (.26%)
Post Procedural Complication
15 (.26%)
Somnolence
15 (.26%)
Device Failure
14 (.25%)
Device Misuse
14 (.25%)
Hyperhidrosis
14 (.25%)
Lethargy
14 (.25%)
No Adverse Event
14 (.25%)
Pulmonary Embolism
14 (.25%)
Wrong Technique In Drug Usage Proce...
14 (.25%)
Adrenal Disorder
13 (.23%)
Adrenal Insufficiency
13 (.23%)
Ankle Fracture
13 (.23%)
Arthritis
13 (.23%)
Benign Intracranial Hypertension
13 (.23%)
Blood Glucose Increased
13 (.23%)
Generalised Oedema
13 (.23%)
Influenza
13 (.23%)
Insulin-like Growth Factor Decrease...
13 (.23%)
Nephrotic Syndrome
13 (.23%)
Road Traffic Accident
13 (.23%)
Cataract
12 (.21%)
Epilepsy
12 (.21%)
Femur Fracture
12 (.21%)
Gastroenteritis
12 (.21%)
Neoplasm
12 (.21%)
Osteoarthritis
12 (.21%)
Abdominal Distension
11 (.19%)
Abdominal Pain
11 (.19%)
Aggression
11 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Humatrope, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Humatrope is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Humatrope

What are the most common Humatrope adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Humatrope, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Humatrope is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Humatrope According to Those Reporting Adverse Events

Why are people taking Humatrope, according to those reporting adverse events to the FDA?

Growth Hormone Deficiency
589
Hypopituitarism
211
Body Height Below Normal
74
Growth Retardation
59
Turners Syndrome
45
Pituitary Tumour
34
Show More Show More
Blood Growth Hormone Decreased
33
Dwarfism
30
Hypothalamo-pituitary Disorder
24
Blood Growth Hormone
22
Hypothalamo-pituitary Disorders
19
Chondrodystrophy
18
Breathing-related Sleep Disorder
14
Prader-willi Syndrome
11
Pituitary Tumour Benign
10
Pituitary Tumour Removal
10
Postpartum Hypopituitarism
7
Blood Growth Hormone Abnormal
7
Prophylaxis
5
Asthenia
5
Small For Dates Baby
4
Bone Density Decreased
4
Hyperpituitarism
4
Osteoporosis
4
Drug Use For Unknown Indication
4
Off Label Use
3
Brain Operation
3
Muscle Mass
3
Foetal Growth Restriction
3
Unevaluable Event
3
Brain Neoplasm
3
Malignant Histiocytosis
2
Pituitary Infarction
2
Renal Disorder
2
Medulloblastoma
2
Hormone Replacement Therapy
2
Hypophysectomy
2
Renal Failure
2
Failure To Thrive
2
Hormone Therapy
2
Acromegaly
2
Laurence-moon-bardet-biedl Syndrome
2
Noonan Syndrome
2
Encephalocele
2
Short-bowel Syndrome
2
Addisons Disease
2
Lymphocytic Hypophysitis
2
Hiv Wasting Syndrome
2
Foetal Growth Retardation
2
Fibromyalgia
2
Post Procedural Complication
1

Drug Labels

LabelLabelerEffective
HumatropeEli Lilly and Company02-AUG-12
HumatropeEli Lilly and Company31-MAR-13

Humatrope Case Reports

What Humatrope safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Humatrope. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Humatrope.